$SDGR

Schrodinger, Inc. Stock 12‑Month Price Target Raised to $21.83, Implies 18% Upside

FactSet-reported analyst estimates show Schrodinger, Inc. (SDGR) average 12-month price target increased to $21.83 from $20.57. Targets range from $17 to $30. Based on the Aug. 13 close, the update implies about 18% upside. The consensus rating remains “Buy” among 6 analysts (5 Buys, 1 Hold, 0 Sells).

Original reporting
Published Aug 14, 2026, 7:20 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Schrodinger, Inc. Stock 12‑Month Price Target Raised to $21.83, Implies 18% Upside — source image
Decision brief

The 30-second read

$SDGRBullishLow
01

Why it matters

For traders, the actionable signal is sentiment drift (PT up, Buy rating unchanged). However, there is no new operational or financial datapoint to reprice fundamentals.

02

Market read

A modest bullish sentiment update for SDGR, but not a standalone fundamental catalyst.

03

What to watch

The article provides only the consensus PT range and rating counts, not the underlying thesis or which analysts changed their models.

Relevance 4/10Novelty 3/10Timing: pre-market today (published 2026-08-14 07:20 UTC)

Background

The piece summarizes FactSet-based consensus analyst estimates for Schrodinger, focusing on the updated 12-month average price target and rating distribution.

Company-level read

Ticker impact

$SDGRBullishMedium confidence
Context

Schrodinger’s average analyst price target rose from $20.57 to $21.83, implying about 18% upside versus the Aug. 13 close.

Expected impact

Likely modest near-term support to sentiment; follow-through depends on whether the market treats the PT change as a catalyst.

Evidence & confidence

The article only reports consensus price-target revisions and unchanged Buy rating mix, with no new earnings, guidance, or operational update.

Market effects

Limited sector read-through since this is a single-name analyst target update without new sector data.

No clear regional spillover indicated.

No global macro or cross-border catalyst mentioned.

Counterpoint

Price-target revisions can lag fundamentals; without new guidance or results, the market may discount the PT change quickly.

Key entities

  • Schrodinger, Inc.

    Consensus analyst price target raised to $21.83 from $20.57; implied upside about 18% vs Aug. 13 close.

Related articles

$GDMedAI 9/10

General Dynamics wins $249m in US military contracts

General Dynamics (GD) won two U.S. military contracts totaling $248.9M. One is a $149.6M contract for USS Pinckney modernization, with potential value up to $149.9M. The other is a $99.3M task order for MUOS Ground Infrastructure Segment upgrades. Both contracts are sole-source and involve work through 2028, funded by fiscal 2026 budgets.

$LMTHighAI 9/10

Lockheed Martin wins $150 million in defense contracts

Lockheed Martin Corp received three contract modifications worth over $150 million from the U.S. Department of Defense. The largest, $90.2 million, is for the TRIDENT II Life Extension 2 program, with work spread across multiple locations. The other contracts, $40.1 million and $20.3 million, are for the MK 41 Vertical Launching System and HH-60W repairs, respectively. Completion dates range from 2027 to 2030.

$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.